Protara Therapeutics

$23.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.22 (-5.00%) Today
$0.00 (0.00%) As of 5:00 PM EST after-hours

Why Robinhood?

You can buy or sell TARA and other stocks, options, and ETFs commission-free!

About TARA

Protara Therapeutics, Inc. Common Stock, also called Protara Therapeutics, is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman in 2017 and is headquartered in New York, NY. The listed name for TARA is Protara Therapeutics, Inc. Common Stock.

CEO
Jesse Shefferman
Employees
12
Headquarters
New York, New York
Founded
2017
Market Cap
260.11M
Price-Earnings Ratio
Dividend Yield
Average Volume
126.83K
High Today
$25.00
Low Today
$22.86
Open Price
$24.93
Volume
46.89K
52 Week High
$67.08
52 Week Low
$10.80

Collections

TARA Earnings

-$29.46
-$19.64
-$9.82
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 18, Pre-Market

You May Also Like